Form4insider filings, from the source

SEC Form 4 · accession 0000919574-17-006860

Avalo Therapeutics, Inc. · AVTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
ARMISTICE CAPITAL, LLC
Director · 10% Owner
Steven Boyd
Director · 10% Owner
Period of report
Sep 18, 2017
Accepted (ET)
Sep 20, 2017 · 5:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534120

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1Sep 18, 2017P6,000$0.7778A15,919,136D
Common StockF2Sep 18, 2017P$00$0.00A15,919,136ISee Footnote
Common StockF2Sep 18, 2017P$00$0.00A15,919,136ISee Footnote
Common StockF1Sep 19, 2017P7,759$0.7501A15,926,895D
Common StockF2Sep 19, 2017P$00$0.00A15,926,895ISee Footnote
Common StockF2Sep 19, 2017P$00$0.00A15,926,895ISee Footnote
Common StockF1Sep 19, 2017P22,360$0.7428A15,949,255D
Common StockF2Sep 19, 2017P$00$0.00A15,949,255ISee Footnote
Common StockF2Sep 19, 2017P$00$0.00A15,949,255ISee Footnote
Common StockF1Sep 20, 2017P15,250$0.7613A15,964,505D
Common StockF2Sep 20, 2017P$00$0.00A15,964,505ISee Footnote
Common StockF2Sep 20, 2017P$00$0.00A15,964,505ISee Footnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
WARRANTSF1,F3$0.40holding————Jun 30, 2022COMMON STOCK14,285,71414,285,714D
WARRANTSF2,F3$0.40holding————Jun 30, 2022COMMON STOCK14,285,71414,285,714I
WARRANTSF2,F3$0.40holding————Jun 30, 2022COMMON STOCK14,285,71414,285,714I

Explanation of responses